Kenneth Marek

Kenneth Marek

Auto-generated profile, based on publicly available information

Kenneth Marek

Institute for Neurodegenerative Disorders New Haven CT

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 October 2018 in Annals of Clinical and Translational Neurology
Verified
Journal Article
Open access
PDF file
KMKenneth Marek
Kenneth Marek
SCSohini Chowdhury
Sohini Chowdhury
ASAndrew Siderowf
Andrew Siderowf
SLShirley Lasch
Shirley Lasch
JCJean-Christophe Corvol
Jean-Christophe Corvol
TIThe Parkinson'S Progression Markers Initiative
The Parkinson'S Progression Markers Initiative
Objective: The Parkinson's Progression Markers Initiative (PPMI) is an observational, international study designed to establish biomarker‐defined cohorts and identify clinical, imaging, genetic, and biospecimen Parkinson's disease (PD) progression markers to accelerate disease‐modifying therapeutic trials.Methods: A total of 423 untreated PD, 196 Healthy Control (HC) and 64 SWEDD (scans without evidence of dopaminergic deficit) subjects were enrolled at 24 sites. To enroll PD subjects as early as possible following diagnosis, subjects were eligible with only asymmetric bradykinesia or tremor plus a dopamine transporter (DAT) binding deficit on SPECT imaging. Acquisition of data was standardized as detailed at www.ppmi-info.org.Results: Approximately 9% of enrolled subjects had a single PD sign at baseline. DAT imaging excluded 16% of potential PD subjects with SWEDD. The total MDS‐UPDRS for PD was 32.4 compared to 4.6 for HC and 28.2 for SWEDD. On average, PD subjects demonstrated 45% and 68% reduction in mean striatal and contralateral putamen Specific Binding Ratios (SBR), respectively. Cerebrospinal fluid (CSF) was acquired from >97% of all subjects. CSF (PD/HC/SWEDD pg/mL) α‐synuclein (1845/2204/2141) was reduced in PD vs HC or SWEDD (P < 0.03). Similarly, t‐tau (45/53) and p‐tau (16/18) were reduced in PD versus HC (P < 0.01),Interpretation: PPMI has detailed the biomarker signature for an early PD cohort defined by clinical features and imaging biomarkers. This strategy provides the framework to establish biomarker cohorts and to define longitudinal progression biomarkers to support future PD treatment trials.

1 December 2001 in Neurology
Verified
Journal Article
Closed access
PDF file
KMK. Marek
K. Marek
RIR. Innis
R. Innis
CDC. van Dyck
C. van Dyck
BFB. Fussell
B. Fussell
MEM. Early
M. Early
JSJ. Seibyl
J. Seibyl
Background: [123I]β-CIT and SPECT imaging of the dopamine transporter is a sensitive biomarker of PD onset and severity. Objective: In this study, the authors examine the change in [123I]β-CIT uptake in sequential SPECT scans to assess the rate of progression of the dopaminergic terminal loss in patients with PD. Methods: Patients with PD (n = 32) and healthy controls (n = 24) recruited from the Yale Movement Disorders Center underwent repeat [123I]β-CIT SPECT imaging during a 1- to 4-year period. The primary imaging outcome was the ratio of specific to nondisplaceable striatal activity. Disease severity was assessed by Hoehn and Yahr staging, and Unified Parkinson Disease Rating Scale after 12 hours off drug. Results: Sequential SPECT scans in PD subjects demonstrated a decline in [123I]β-CIT striatal uptake of approximately 11.2%/year from the baseline scan, compared with 0.8%/year in the healthy controls (p < 0.001). Although [123I]β-CIT striatal uptake in the PD subjects was correlated with clinical severity, the annual percentage loss of [123I]β-CIT striatal uptake did not correlate with the annual loss in measures of clinical function. Conclusions: The rate of dopaminergic loss in PD is significantly greater than that of healthy controls, and [123I]β-CIT SPECT imaging provides a quantitative biomarker for the progressive nigrostriatal dopaminergic degeneration in PD. As new protective and restorative therapies for PD are developed, dopamine transporter imaging offers the potential to provide an objective endpoint for these therapeutic trials.

1 August 2017 in JAMA Neurology
Verified
Journal Article
Open access
PDF file
DJDanna Jennings
Danna Jennings
ASAndrew Siderowf
Andrew Siderowf
MSMatthew Stern
Matthew Stern
JSJohn Seibyl
John Seibyl
SEShirley Eberly
Shirley Eberly
FIfor the PARS Investigators
for the PARS Investigators
Emerging evidence from preclinical and biomarker studies indicates that the pathology underlying neurodegenerative diseases begins many years before a clinical diagnosis is apparent.1,2 In Parkinson disease (PD), the second most common neurodegenerative disorder with a societal cost of more than $15 billion (2010-adjusted) per year in the United States,3 there is a prodromal phase characterized by pathologic alterations in dopaminergic integrity and subtle nonmotor features in the absence of cardinal motor signs.1 Earlier detection of PD would enable testing of potential disease-modifying treatments when pathology is less advanced and when treatments may be more effective.4 Identifying individuals with prodromal PD requires an assessment strategy that is both widely available and highly specific. We describe a sequential biomarker paradigm, starting with a highly sensitive, widely available tool (olfaction) to identify a risk group followed by a highly specific test (dopamine transporter [DAT] imaging) to confirm a high-risk group.

20 May 2014 in Neurology
Verified
Journal Article
Closed access
PDF file
KMKenneth Marek
Kenneth Marek
JSJohn Seibyl
John Seibyl
SEShirley Eberly
Shirley Eberly
DODavid Oakes
David Oakes
ISIra Shoulson
Ira Shoulson
FIFor The Parkinson Study Group PRECEPT Investigators
For The Parkinson Study Group PRECEPT Investigators
Objective: To compare the clinical and imaging characteristics of those PRECEPT (Parkinson Research Examination of CEP-1347 Trial) subjects with a scan without evidence of dopaminergic deficit (SWEDD) to those with dopamine transporter (DAT) deficit scans at study baseline and during a 22-month follow-up. Methods: Baseline (n = 799) and 22-month follow-up (n = 701) [123I] β-CIT SPECT scans were acquired. The percent change in [123I] β-CIT striatal binding ratio, the percentage of subjects requiring dopaminergic therapy, the change in Unified Parkinson9s Disease Rating Scale (UPDRS) score, and the PRECEPT Study investigators’ diagnosis at study termination were compared between SWEDD and DAT deficit subjects. Results: SWEDD subjects (n = 91) compared with DAT deficit subjects (n = 708) showed reduced UPDRS score at baseline (18.7 [SD 8.5] vs 25.5 [SD 10.5], p < 0.05) and minimal change in both [123I] β-CIT striatal binding ratio (−0.2% [SD 12.2] vs −8.5% [SD 11.9], p < 0.0001) and UPDRS score (0.5 [SD 6.9] vs 10.5 [SD 8.9], p < 0.0001) at follow-up assessments. At PRECEPT termination, the diagnosis by study investigators was changed from Parkinson disease (PD) to other disorders not associated with DAT deficit in 44% (95% confidence interval 34.2, 54.7) of SWEDD subjects compared with 3.6% (95% confidence interval 2.3, 5.1) of DAT deficit subjects. Conclusion: These results indicate that subjects identified as having a SWEDD, with DAT imaging within the normal range, have minimal evidence of clinical or imaging PD progression. These data strongly suggest that SWEDD subjects are unlikely to have idiopathic PD.

17 February 2009 in Neurology
Verified
Journal Article
Closed access
PDF file
KMKenneth Marek
Kenneth Marek
DJDanna Jennings
Danna Jennings
Pathology and imaging studies have shown that patients with Parkinson disease (PD) have a prolonged period of uncertain duration when vulnerable neuronal populations are degenerating, but typical motor symptoms have not yet developed. This provides both an opportunity—it may be best to test new medications and, ultimately, treat PD patients during this early phase of disease—and a challenge—how to find these premotor PD subjects? Imaging biomarkers targeting the premotor period are critical to elucidate both the onset and progression of premotor PD. Widespread data have demonstrated that dopaminergic imaging can detect PD subjects at the motor symptom threshold. Novel strategies combining dopaminergic imaging with known genetic mutations for PD or early clinical signs and PD-associated symptoms, such as olfactory loss and sleep disturbances like REM behavior disorder, have begun to be used to identify individuals at risk for PD before motor symptoms become manifest. Early studies also have used imaging targeting norepinephrine, serotonin, cholinergic, or other neuronal systems to focus on early cardiac, cognitive, and behavioral symptoms. Imaging of nondopaminergic targets such as inflammation or α-synuclein deposition may provide further insight into the etiology of PD. Given the multiple genetic etiologies for PD already identified, the marked variability in the loss of dopaminergic markers measured by imaging at motor symptom onset, and the clear heterogeneity of clinical symptoms at PD onset, it is certain that many imaging biomarkers with a focus ranging from clinical symptoms to PD pathobiology to molecular genetic mechanisms, will be necessary to fully map PD risk.

19 February 2020 in Movement Disorders
Verified
Journal Article
Open access
PDF file
TSTanya Simuni
Tanya Simuni
MBMichael C. Brumm
Michael C. Brumm
LULiz Uribe
Liz Uribe
CCChelsea Caspell‐Garcia
Chelsea Caspell‐Garcia
CCChristopher S. Coffey
Christopher S. Coffey
PIParkinson's Progression Markers Initiative Investigators
Parkinson's Progression Markers Initiative Investigators
Background: There are limited data on the phenotypic and dopamine transporter (DAT) imaging characterization of the Parkinson's disease (PD) patients with leucine rich kinase 2 (LRRK2) and glucosylceramidase beta (GBA) mutations.Objective: The objective of this study was to examine baseline clinical and DAT imaging characteristics in GBA and LRRK2 mutation carriers with early PD compared with sporadic PD.Methods: The Parkinson's Progression Markers Initiative is an ongoing observational longitudinal study that enrolled participants with sporadic PD, LRRK2 and GBA PD carriers from 33 sites worldwide. All participants are assessed annually with a battery of motor and nonmotor scales, 123‐I Ioflupane DAT imaging, and biologic variables.Results: We assessed 158 LRRK2 (89% G2019S), 80 GBA (89 %N370S), and 361 sporadic PD participants with the mean (standard deviation) disease duration of 2.9 (1.9), 3.1 (2.0), and 2.6 (0.6) years, respectively. When compared with sporadic PD, the GBA PD patients had no difference in any motor, cognitive, or autonomic features. The LRRK2 PD patients had less motor disability and lower rapid eye movement behavior disorder questionnaire scores, but no meaningful difference in cognitive or autonomic features. Both genetic cohorts had a higher score on the impulse control disorders scale when compared with sporadic PD, but no difference in other psychiatric features. Both genetic PD cohorts had less loss of dopamine transporter on DAT imaging when compared with sporadic PD.Conclusions: We confirm previous reports of milder phenotype associated with LRRK2‐PD. A previously reported more aggressive phenotype in GBA‐PD is not evident early in the disease in N370s carriers. This observation identifies a window for potential disease‐modifying interventions. Longitudinal data will be essential to define the slope of progression for both genetic cohorts.Trial Registration: ClinicalTrials.gov (NCT01141023). © 2020 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.